Key Drivers
- Strong Margins
- FCF Coverage
- Thin Liquidity
AIAI Summary
Sanofi is evolving from a dependable dividend pharma into a “prove-it” growth story where strong cash generation and a well-covered payout support the downside, but investors should focus on whether Dupixent expansion plus newer franchises like Tzield, Sarclisa, and Nexviazyme can scale fast enough to offset pipeline inconsistency and the looming 2031 exclusivity overhang.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •FCF Coverage
- •Thin Liquidity
SNY combines strong margins, robust free cash flow, and solid dividend coverage with a reasonable valuation, but leverage, thin liquidity, and a large intangible-heavy asset base temper the overall risk profile.
Price Behavior
Key Price Behavior Insights:
- •Range-bound trading
- •Support rebound
- •Resistance capped
SNY was range-bound over the last month, with an ~8% mid-period drop to support at $41.3-$41.8 followed by a partial rebound, leaving the stock neutral to mildly constructive until it reclaims $44.2-$45.0.
Roughly 8% drop to $41.33 followed by a rebound to $43.16
Sentiment & News
Key News Insights:
- •Dupixent Growth
- •Regulatory Wins
- •Trial Setback
Sanofi's recent headlines were driven by strong Dupixent-led growth and multiple regulatory/clinical wins, partly offset by a neurology trial setback and an EU antitrust probe.
The news flow is modestly positive overall, supporting Sanofi's near-term outlook while keeping pipeline, exclusivity, and legal risks in focus
Similar Companies in Healthcare
Other companies in the same sector with AI ratings